MMV-supported projects



Global Fund Expert Review Panel (ERP) reviewed product - permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.

 Included in MMV portfolio after product approval.

WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.

* A single dose of 500/25mg SP on Day 1. 150mg AQ given once daily on Day 1, 2 and 3.

** A single dose of 250/12.5mg SP on Day 1. 75mg AQ given once daily on Day 1, 2, and 3.

Brand names:

1 Coartem® Dispersible
2 Artesun® 
3 Eurartesim®
4 Pyramax® tablets or granules
5 ASAQ Winthrop® 

Target Product Profiles - represented by coloured bar(s) under the project box

____  3-day cure, artemisinin-based combination therapies

____  Combinations aiming at a new Single exposure radical cure 

____  Severe malaria and pre-referral treatment

____  Intermittent/Seasonal Malaria Chemoprevention

____  Products targeting prevention of relapse for P. vivax

Target Candidate Profiles- represented by icons

 Asexual blood stages

 Relapse prevention

 Transmission reduction